PARPi sensitivity was positively correlated with sensitivity to oxaliplatin, and treatment with olaparib impaired tumor growth; in addition, maintenance therapy with PARP blockade after initial oxaliplatin response delayed disease progression in mice. The gene discussed is PARP1; the disease is neoplasm.